Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease
- PMID: 22521350
- DOI: 10.1016/j.jhep.2012.03.013
Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease
Abstract
Background & aims: Visceral adiposity is associated with hepatic steatosis, inflammation, and fibrosis in non-alcoholic fatty liver disease (NAFLD). The visceral adiposity index (VAI), a novel marker of visceral fat distribution and dysfunction, has been correlated with histology in hepatitis C. We assessed the ability of VAI to predict disease severity in NAFLD and hence its role as a non-invasive marker of liver damage.
Methods: We examined 190 adults with biopsy-proven NAFLD and 129 controls. All had anthropometric and metabolic profiling. VAI was calculated using waist circumference (WC), body mass index, triglycerides, and HDL-cholesterol. Abdominal fat was quantified by magnetic resonance imaging (MRI) in 38 patients.
Results: On multivariate analysis, NAFLD diagnosis and fasting glucose were independently associated with VAI (p <0.05). VAI increased across control, steatosis, and NASH groups (1.5, 2.3, and 3.2, respectively; p=0.000), however, this association was no stronger than the increase in WC across groups (r=0.452 vs. 0.540 respectively, p <0.001). VAI was not associated with steatosis, lobular inflammation or fibrosis, but WC was associated with fibrosis (p=0.01). VAI and WC correlated with an increasing number of metabolic syndrome components (r=0.623 vs. 0.614, p <0.001) and with metabolic syndrome diagnosis (r=0.559 vs. 0.509, p <0.001). VAI only modestly correlated with visceral fat on MRI (r=0.39, p <0.05) compared to WC (r=0.52, p <0.01).
Conclusions: In NAFLD, VAI is not associated with steatosis, inflammation or fibrosis. VAI is no more powerful than WC in discriminating steatosis from steatohepatitis, reflecting limitations of the formula with what is known about the pathogenesis of NAFLD.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2012 Jan;35(2):238-47. doi: 10.1111/j.1365-2036.2011.04929.x. Epub 2011 Nov 24. Aliment Pharmacol Ther. 2012. PMID: 22117531
-
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.J Hepatol. 2011 Jun;54(6):1244-9. doi: 10.1016/j.jhep.2010.09.037. Epub 2010 Nov 11. J Hepatol. 2011. PMID: 21145841
-
Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients.Rev Esp Enferm Dig. 2014 Dec;106(8):522-8. Rev Esp Enferm Dig. 2014. PMID: 25544409
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.Biomedicines. 2021 Dec 13;9(12):1890. doi: 10.3390/biomedicines9121890. Biomedicines. 2021. PMID: 34944706 Free PMC article. Review.
Cited by
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Effect of sustained decreases in sedentary time and increases in physical activity on liver enzymes and indices in type 2 diabetes.Front Endocrinol (Lausanne). 2024 May 24;15:1393859. doi: 10.3389/fendo.2024.1393859. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38854689 Free PMC article. Clinical Trial.
-
Vitamin D and the Metabolic Phenotype in Weight Loss After Bariatric Surgery: A Longitudinal Study.Obes Surg. 2024 May;34(5):1561-1568. doi: 10.1007/s11695-024-07148-x. Epub 2024 Mar 8. Obes Surg. 2024. PMID: 38459277
-
Development and Validation of a Nomogram for Prediction of the Risk of MAFLD in an Overweight and Obese Population.J Clin Transl Hepatol. 2022 Dec 28;10(6):1027-1033. doi: 10.14218/JCTH.2021.00317. Epub 2022 Feb 28. J Clin Transl Hepatol. 2022. PMID: 36381091 Free PMC article.
-
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.J Hepatol. 2023 Feb;78(2):238-246. doi: 10.1016/j.jhep.2022.10.027. Epub 2022 Nov 8. J Hepatol. 2023. PMID: 36368598 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources